Invivyd, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- William E. Duke Jr.
- Full Time Employees
- 99
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1601 Trapelo Road Waltham MA United States of America 02451
- IPO Date
- Aug 6, 2021
- CIK
- 0001832038
- Website
- adagiotx.com
- Similar Companies
- Business
- Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based therapies for serious infectious diseases with pandemic potential, beginning with SARS-CoV-2 and expanding into influenza, respiratory syncytial virus (RSV), measles, and other high-need indications; its proprietary INVYMAB platform integrates viral surveillance, predictive modeling, and advanced antibody engineering to generate monoclonal antibodies (mAbs) that outperform natural immunity by anticipating viral evolution. Core products and pipeline candidates include PEMGARDA (pemivibart), an FDA-authorized half-life extended mAb for pre-exposure prophylaxis of COVID-19 in immunocompromised adults and adolescents; VYD2311, an investigational mAb advancing in the Phase 3 REVOLUTION program (including the DECLARATION pivotal trial and LIBERTY head-to-head study versus mRNA vaccines) for COVID-19 prevention and treatment, with FDA IND approval and trial initiation targeted for late 2025; VBY329, a nominated best-in-class RSV mAb candidate for neonatal, infant, and pediatric prevention targeting multiple variants, with IND readiness planned for the second half of 2026; and earlier candidates such as adintrevimab (in Phase 2/3 for COVID-19 prevention/treatment) and preclinical programs for Long COVID via the SPEAR Study Group. Founded in 2020 and headquartered in Waltham, Massachusetts, the company operates primarily in the United States, targeting vulnerable populations including immunocompromised individuals, neonates, and those with post-vaccination syndromes. Recent developments include a $125 million public equity offering priced in November 2025 (comprising common stock and pre-funded warrants) to fund VYD2311 commercialization readiness, RSV/measles R&D, and general purposes following an August 2025 $50 million offering for similar pipeline advancement; nomination of VBY329 for preclinical development in November 2025 signaling platform expansion beyond COVID-19; FDA clearance of the VYD2311 IND with Phase 3 trial guidance in late 2025; and positive in vitro data for PEMGARDA against emerging SARS-CoV-2 variants.
Invivyd Announces Receipt of Twelve Months' Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine
Invivyd doses first participants in Phase 3 COVID-19 trial
Invivyd doses first participants in Phase 3 COVID-19 trial
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID
Invivyd to Participate in Upcoming Investor Events
Invivyd to Participate in Upcoming Investor Events
Invivyd, Inc. (IVVD) Q1 2026 Earnings Call Transcript
Invivyd Q1 Earnings Call Highlights
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates
Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights
Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination
Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit
Invivyd, Inc. (IVVD) Discusses Progress in REVOLUTION Clinical Program and Advancement of Measles Monoclonal Antibody Candidate Transcript